Summary

Report Overview
The Global Diffusive Alveolar Hemorrhage Treatment Market reached US$ 562 million in 2023 and is expected to reach US$ 926 million by 2031, growing at a CAGR of 6.6% during the forecast period 2024-2031. 
Diffusive alveolar hemorrhage is a life-threatening condition in which bleeding happens in the alveolar spaces of the lung. The bleeding can be caused by injury or inflammation in the arterioles venules, or alveolar septal capillaries. The symptoms of diffusive alveolar hemorrhage are dyspnea, hemoptysis, cough, etc. Diffusive alveolar hemorrhage (DAH) is caused by conditions such as systemic vasculitis, good posture syndrome, systemic lupus erythematosus (SLE), pulmonary infections, toxic compound exposures, coagulation disorders, and cardiac disorders.
Market Dynamics: Drivers
Rising prevalence of diffusive alveolar hemorrhage
The prevalence of diffusive alveolar hemorrhage is not well documented, due to the rarity of the condition. However, several autoimmune conditions majorly precipitate the condition. Among these, systemic lupus erythematosus (SLE), and systemic vasculitis are the major autoimmune conditions behind DAH. As their incidence rises, the incidence of DAH is also anticipated to rise. With the advancements in diagnostics, the target population for treatment also rises, contributing to the overall market growth.
For instance, according to a global epidemiology study published in the Annals of Rheumatic Disease journal in October 2022, the annual incidence of systemic lupus erythematosus is 5.14 per 100,000 person-years. As per DataM estimates, this reflects a total of 413,530 cases of SLE in 2023. Upon literature review, the incidence of alveolar hemorrhage among SLE patients ranges from 0.6% to 5.4% per 100,000 patient-years, which makes the total incidence of 12,467 diffusive alveolar hemorrhage patients in 2023, caused by SLE.
However, this number only makes up a specific portion of total DAH patients worldwide. The condition can be caused by various conditions such as infections, cardiac disorders, toxin exposures, etc. As the incidence rises, the total prevalence of DAH is also anticipated to rise in the future, which is the major growth driving factor for the market in the forecast period.
Restraints
The market for diffusive alveolar hemorrhage treatment is restrained by several factors such as limited patient population i.e., rarity of the condition, lack of specific treatment options, and high mortality rate. For the manufacturers to develop a specific treatment option, there should be an appropriate number of patient population to conduct clinical trials and validate the efficacy of their innovative treatment. Due to lack of sufficient patient population, the manufacturers may not focus on innovations, which may limit the treatment options and restrain the market growth.
Market Segment Analysis
The global diffusive alveolar hemorrhage treatment market is segmented based on type, treatment type, patient type, and region.
Pharmacotherapy in the treatment type segment accounted for approximately 71.3% of the global diffusive alveolar hemorrhage treatment  market share
Diffusive alveolar hemorrhage is majorly caused by underlying autoimmune conditions such as systemic lupus erythematosus, Wegener's granulomatosis, Goodpasture syndrome, etc. To treat DAH, it is the primary step to treat the underlying conditions. Drugs such as steroids and immunosuppressants remain the mainstay therapeutic options for this condition.
Steroids such as prednisolone, and methylprednisolone remain the first-line therapeutic agents. In addition, immunosuppressant drugs are prescribed for autoimmune destruction. These immunosuppressants include cyclophosphamide, azathioprine, methotrexate. In the past decade, Rituximab was added to this list, which is effective for immunosuppression. Rituximab is a monoclonal antibody which acts by suppressing ANCA-producing CD20(+) plasma cells. By the combination prescription of Steroids and immunosuppressants, the mortality rate can be hugely reduced. 
In addition to these standard treatments, to effectively stop bleeding, various prothrombotic factors including antifibrinolytics, thrombin, and FVIIa can be given, but these agents have very little clinical evidence and are only prescribed for off-label use. 
Market Geographical Analysis 
North America dominates the global diffusive alveolar hemorrhage treatment market with a share of 43.3% in 2023
North America dominates the global diffusive alveolar hemorrhage treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.
Autoimmune conditions such as systemic lupus erythematosus, and systemic vasculitis are the main culprits behind diffusive alveolar hemorrhage (DAH). As their prevalence is rising, the incidence of DAH is anticipated to rise in the region. For instance, according to Centers for Disease Control and Prevention (CDC), estimated there are 204,000 patients with SLE in the U.S. According to the literature review, among SLE patients, alveolar hemorrhage incidence ranges from 1% to 5.4% of lupus patients, which accounts for approximately 6150 (1,285-11,016) cases as per DataM estimates.
Although the condition is very rare, the region’s advanced healthcare facilities and diagnostic centers actively diagnose the patient and improve the treatment rate. This combined with the availability of gold-standard drugs such as rituximab, and cyclophosphamide offered by leading pharmaceutical companies like Roche, Amgen, Pfizer, etc. improve the overall number of patients receiving the treatment.
Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.
Market Segmentation
By Type
Autoimmune Induced Alveolar Hemorrhage
Drug-Induced Alveolar Hemorrhage
Infection Induced Alveolar Hemorrhage
Others
By Treatment Type
Pharmacotherapy
Steroids
Immunosuppressants
Cyclophosphamide
Rituximab
Azathioprine
Others
Others
Plasma Exchange Therapy
Supportive Care
By Patient Type
Pediatrics
Adults
Geriatrics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major players in the diffusive alveolar hemorrhage treatment market include F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals., Teva Pharmaceuticals USA, Inc., Amgen Inc., Baxter., Pfizer Inc., GSK plc, Horizon Therapeutics plc, Sandoz AG, and Sun Pharmaceutical Industries Ltd. among others.
Why Purchase the Report?
To visualize the global diffusive alveolar hemorrhage treatment market segmentation based on type, treatment type, patient type, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of diffusive alveolar hemorrhage treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global diffusive alveolar hemorrhage treatment market report would provide approximately 62 tables, 53 figures, and 175 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by Patient Type
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of diffusive alveolar hemorrhage
4.1.1.2. Advancements in diagnostics and increasing treatment rate
4.1.2. Restraints
4.1.2.1. Lack of specific treatment options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Unmet Needs
5.5. PESTEL Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Autoimmune Induced Alveolar Hemorrhage*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Drug-Induced Alveolar Hemorrhage
6.4. Infection Induced Alveolar Hemorrhage
6.5. Others
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Pharmacotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Steroids
7.4. Immunosuppressants
7.4.1. Cyclophosphamide
7.4.2. Rituximab
7.4.3. Azathioprine
7.4.4. Others
7.5. Plasma Exchange Therapy
7.6. Supportive Care
8. By Patient Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
8.4. Geriatrics
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.2. Germany
9.3.5.3. UK
9.3.5.4. France
9.3.5.5. Italy
9.3.5.6. Spain
9.3.5.7. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.2. Brazil
9.4.5.3. Argentina
9.4.5.4. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.2. China
9.5.5.3. India
9.5.5.4. Japan
9.5.5.5. South Korea
9.5.5.6. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. F. Hoffmann-La Roche Ltd.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Cadila Pharmaceuticals.
11.3. Teva Pharmaceuticals USA, Inc.
11.4. Amgen Inc.
11.5. Baxter.
11.6. Pfizer Inc.
11.7. GSK plc
11.8. Horizon Therapeutics plc
11.9. Sandoz AG
11.10. Sun Pharmaceutical Industries Ltd. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us